Degarelix Acetate (Firmagon®)

Common name: Degarelix Acetate
Brand name: Firmagon®
 

What is Degarelix Acetate?

Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat advanced (metastatic) prostate cancer by blocking the release of testosterone.
 

How is Degarelix Acetate administered?

Degarelix Acetate is administered by subcutaneous injection in the abdominal area.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received degarelix acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Breast enlargement
  • Constipation
  • Difficulties sleeping
  • Fatigue
  • Frequent urination
  • Headaches
  • Hot flashes
  • Nausea
  • Pain / redness at site of injection
  • Reduced sex drive (low libido)


Is Degarelix Acetate covered in my province or territory?*

Degarelix acetate is covered by provincial drug programs in:
  • British Columbia
  • New Brunswick
  • Northwest Territories
  • Nova Scotia
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan

Degarelix acetate may be covered by provincial drug programs after individual review in:
  • Manitoba
​Degarelix acetate is not covered by provincial drug programs in:
  • ​Alberta
  • Newfoundland & Labrador
  • Yukon

Unknown if degarelix acetate is covered by provincial drug programs in:
  • Nunavut

Firmagon Care Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications and/or financial assistance to those who cannot afford to pay for their medicine.

Please call 1-855-982-6348 for more information and to see if you qualify for this program.


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=21330

Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive